Lalwani Nikhil sold $401K of ANIP

ANI Pharma reported positive phase 4 trial results for Iluvien in treating non-infectious uveitis. The study met both primary endpoints, showing improvements in patients' conditions. According to the company, the findings demonstrate the drug's effectiveness in this area.

ANI Pharmaceuticals (ANIP) reported positive results from its Phase 4 SYNCHRONICITY trial for the Fluocinolone Acetonide Intravitreal Implant in treating chronic non-infectious uveitis affecting the posterior segment of the eye. The trial met primary endpoints at six months and maintained improvements through 24 months. The implant is approved in the U.S. for chronic NIU-PS and diabetic macular edema. ANIP's stock closed at $73.89, up 2.65%.

ANI Pharmaceuticals (NASDAQ:ANIP) reported positive Phase 4 trial results for its fluocinolone acetonide implant in treating chronic non-infectious uveitis. The trial met primary endpoints, showing sustained improvements in visual acuity and central subfield thickness over 24 months. Adverse events included ocular hypertension and cataract. The implant was previously FDA-approved for diabetic macular edema and uveitis treatment.

ANI Pharmaceuticals reported 6-month and 24-month data from its SYNCHRONICITY trial of fluocinolone acetonide intravitreal implant for chronic non-infectious uveitis. The trial met co-primary endpoints with statistical significance, showing improvements in visual acuity and central subfield thickness. At 24 months, 79.6% of treated eyes had no inflammation recurrence. Adverse events were consistent with prior trials.

ANI Pharmaceuticals (ANIP) will present data from its Phase 4 SYNCHRONICITY trial and post-hoc analyses from the NEW DAY trial at the American Academy of Ophthalmology 2026 Meeting. The trials involve Fluocinolone Acetonide Intravitreal Implant for chronic non-infectious uveitis and diabetic macular edema. The company also plans an encore presentation at the Hawaiian Eye & Retina 2027 Meeting.

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.